A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

July 11, 2013

Primary Completion Date

October 8, 2020

Study Completion Date

December 3, 2020

Conditions
Advanced Solid TumorLymphoma
Interventions
DRUG

Milademetan

DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.

DRUG

Milademetan

Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.

Trial Locations (5)

10032

Columbia University College of Physicians and Surgeons, New York

10065

Memorial Sloan Kettering Cancer Center, New York

37203

Tennessee Oncology, Nashville

48201

Karmanos Cancer Institute, Detroit

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT01877382 - A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas | Biotech Hunter | Biotech Hunter